Fort Collins, United States
PhotonPharma, an immuno-oncology pioneer founded in 2018, is revolutionizing cancer treatment with its innovative approach of leveraging the body’s immune system to combat cancer. The company’s unique selling proposition rests in its break-through technology, which, through a patent-protected process, inactivates the DNA/RNA of the tumor cells—while preserving the critical neoantigens required for targeted immune responses. This method promises operational efficiency by enabling same-day tumor cell extraction, inactivation, and administration back to the patient.
The simplicity, speed, and affordability of the process bring forward a compelling investment thesis, as evidenced by successful trials in companion animals and mouse studies. With a recent $2.50M Seed investment in August 2024, PhotonPharma appears well-positioned to further its development trajectory and potentially disrupt the immuno-oncology sector. Their promising technology and strategic approach present an intriguing opportunity for investors to participate in a transformative healthcare innovation.
